President Donald Trump says he’ll signal an govt order on Monday that, if applied, might convey down the prices of some medicines — reviving a failed effort from his first time period on a difficulty he is talked up since even earlier than changing into president.
The order Trump is promising will direct the Division of Well being and Human Companies to tie what Medicare pays for medicines administered in a health care provider’s workplace to the lowest worth paid by different international locations.
“I will be instituting a MOST FAVORED NATION’S POLICY whereby the United States will pay the same price as the Nation that pays the lowest price anywhere in the World,” the president posted Sunday on his social media website, pledging to signal the order on Monday morning on the White Home.
“Our Country will finally be treated fairly, and our citizens Healthcare Costs will be reduced by numbers never even thought of before,” Trump added.
His proposal would seemingly solely influence sure medication coated by Medicare and given in an workplace — assume infusions that deal with most cancers, and different injectables. But it surely might probably convey vital financial savings to the federal government, though the “TRILLIONS OF DOLLARS” Trump boasted about in his publish could also be an exaggeration.
Medicare offers medical health insurance for roughly 70 million older Individuals. Complaints about U.S. drug costs being notoriously excessive, even in comparison with different giant and rich international locations, have lengthy drawn the ire of each events, however a long-lasting repair has by no means cleared Congress.
Beneath the deliberate order, the federal authorities would tie what it pays pharmaceutical corporations for these medication to the worth paid by a bunch of different, economically superior international locations — the so-called “most favored nation” method.
The proposal will face fierce opposition from the pharmaceutical business.
It was a rule that Trump tried to undertake throughout his first time period, however might by no means get by. He signed a comparable govt order within the remaining weeks of his presidency, however a court docket order later blocked the rule from going into impact below the Biden administration.
The pharmaceutical business argued that Trump’s 2020 try would give international governments the “upper hand” in deciding the worth of medicines within the U.S.. The business has lengthy argued that forcing decrease costs will damage income, and finally have an effect on innovation and its efforts to develop new medicines.
Solely medication on Medicare Half B — the insurance coverage for physician’s workplace visits — are prone to be coated below the plan. Medicare beneficiaries are chargeable for selecting up a number of the prices to get these medicines throughout physician’s visits, and for conventional Medicare enrollees there is no such thing as a annual out-of-pocket cap on what they pay.
A report by the Trump administration throughout its first time period discovered that the U.S. spends twice as a lot as another international locations in protecting these medication. Medicare Half B drug spending topped $33 billion in 2021.
Extra widespread prescribed drugs stuffed at a pharmacy would most likely not be coated by the brand new order.
Trump’s publish formally previewing the motion got here after he teased a “very big announcement” final week. He gave no particulars, besides to notice that it wasn’t associated to commerce or the tariffs he has introduced imposing on a lot of the world.
“We’re going to have a very, very big announcement to make — like as big as it gets,” Trump stated final week.
He got here into his first time period accusing pharmaceutical corporations of “getting away with murder” and complaining that different international locations whose governments set drug costs have been profiting from Individuals.
On Sunday, Trump took intention on the business once more, writing that the “Pharmaceutical/Drug Companies would say, for years, that it was Research and Development Costs, and that all of these costs were, and would be, for no reason whatsoever, borne by the ‘suckers’ of America, ALONE.”
Referring to drug corporations’ highly effective lobbying efforts, he stated that marketing campaign contributions “can do wonders, but not with me, and not with the Republican Party.”
“We are going to do the right thing,” he wrote.
This story was initially featured on Fortune.com
